Charles River Laboratories | CRL - Current Liabilities


Charles River Laboratories reported $1.13B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Agilent USD 2.27B 35M Mar/2026
Align Technology USD 1.91B 2.74M Jun/2026
Bio-Rad Laboratories USD 961.3M 44.3M Jun/2026
Bruker USD 1.2B 150.4M Jun/2026
Cardinal Health USD 43.9B 1.92B Jun/2026
Charles River Laboratories USD 1.13B 41.04M Jun/2026
Cigna USD 55.56B 2.96B Jun/2026
Concord Medical Services Hldg CNY 1.95B 499.89M Dec/2025
CVS Health USD 87.04B 635M Jun/2026
Danaher USD 8.1B 645M Jun/2026
Dentsply International USD 1.18B 22M Jun/2026
Elevance Health USD 44.25B 1.06B Jun/2026
Humana USD 21.51B 5.16B Mar/2026
Illumina USD 1.58B 12M Jun/2026
Incyte USD 1.31B 177.55M Jun/2026
Intrexon USD 23.02M 38K Jun/2024
IQVIA Holdings USD 8.82B 486M Jun/2026
Laboratory Of America USD 2.12B 516.4M Jun/2026
Lakefront Biotherapeutics EUR 70.32M 30.1M Jun/2026
Lonza CHF 3.57B 421M Dec/2025
McKesson USD 70.36B 3.34B Jun/2026
Merck EUR 8.12B 1.22B Jun/2026
Mettler Toledo International USD 1.2B 92.14M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Quest Diagnostics USD 1.79B 389M Jun/2026
Revvity USD 1.28B 37.71M Jun/2026
Thermo Fisher Scientific USD 15.07B 448M Jun/2026
United Therapeutics USD 607.8M 8.7M Jun/2026
UnitedHealth USD 111.82B 2.3B Jun/2026
Veradigm USD 230.31M 22.78M Dec/2022
Waters USD 2.27B 1.03B Mar/2026
West Pharmaceutical Services USD 640.5M 33.5M Jun/2026